Related Experiment Video
Updated: Jul 6, 2025
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.5K
Chapter 1: The Burden of Heart Failure
Richard Pratley1, Xuan Guan2, Richard J Moro3
1AdventHealth Translational Research Institute, Orlando, Fla.
The American Journal of Medicine
|January 6, 2024
Summary
Heart failure (HF) is a growing concern, affecting millions and increasing healthcare costs. Early diagnosis and new treatments offer hope for better survival and quality of life for patients with this condition.
Area of Science:
- Cardiology
- Public Health
Background:
- Heart failure (HF) affects 6 million American adults, with increasing prevalence due to aging and diabetes.
- Improved survival leads to more individuals living longer with HF, impacting quality of life and increasing morbidity and mortality.
- HF management incurs significant healthcare costs, primarily from hospitalizations.
Purpose of the Study:
- To highlight the growing burden of heart failure.
- To emphasize the role of clinicians in HF management.
- To underscore the importance of prevention and early diagnosis.
Main Methods:
- This abstract reviews current trends and challenges in heart failure management.
- It discusses the impact of comorbidities and advances in pharmacotherapy.
Main Results:
- Heart failure prevalence is rising, driven by demographic and comorbidity factors.
- Effective treatments and early diagnosis are crucial for reducing HF burden.
- Pharmacotherapies show potential for improving HF patient outcomes.
Conclusions:
- Timely diagnosis and access to effective treatments are essential for managing heart failure.
- Prevention and early detection are key to mitigating the increasing impact of HF.
- Advances in pharmacotherapy may significantly improve survival and quality of life for HF patients.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: Diuretics
388
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
388
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591